Sanofi’s shift to immunology, AI-driven R&D, and strong pipeline offset risks from patent cliffs and legal issues. See why ...

Sanofi has struck a deal to buy Vicebio for $1.15 billion upfront, securing a phase 1 vaccine candidate to expand its RSV pipeline beyond mRNA.

The vaccine candidate complements Sanofi’s position in the respiratory vaccines space, where the company is present in flu and RSV prevention.

Sanofi Q2 sales rose 10.1% at constant currency, led by Dupixent and ALTUVIIIO. EPS missed estimates; 2025 sales guidance was ...

Sanofi to acquire Vicebio, expanding respiratory vaccines pipeline Paris, July 22, 2025. Sanofi today announces it has entered into an agreement to acquire Vicebio Ltd (“Vicebio”), a privately ...

Sanofi to acquire Vicebio, expanding respiratory vaccines pipeline. Paris, July 22, 2025. Sanofi today announces it has entered into an agreement to acquire Vicebio Ltd, a privately held ...

Effectiveness seen for RSV lower respiratory tract disease, hospitalized RSV lower respiratory tract disease, PCR-confirmed RSV.

The vaccine candidate complements Sanofi’s position in the respiratory vaccines space where the company is present in flu and RSV prevention. It allows Sanofi to offer increased physician and ...

BEYFORTUS® reduced hospital and doctor visits for RSV disease in babies by 87%, according to largest US real-world study ...